-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Hepatocellular Carcinoma Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HUC-3431 in Idiopathic (Essential) Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HUC-3431 in Idiopathic (Essential) Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HUC-3431 in Idiopathic (Essential) Hypertension Drug Details: HUC3-431 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ESP-01 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ESP-01 in Metastatic Colorectal Cancer Drug Details: ESP-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-907828 in Dedifferentiated Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-907828 in Dedifferentiated Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-907828 in Dedifferentiated Liposarcoma Drug Details: BI-907828 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-442257 in Cutaneous T-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-442257 in Cutaneous T-Cell Lymphoma Drug Details: SAR-442257 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Epithelial Ovarian Cancer Drug Details: Spartalizumab (PDR-001) is under...
-
Product Insights
BMB (Barnowko – Mostno – Buszewo) Field
BMB (Barnowko - Mostno - Buszewo) Field is a producing field located in West Pomeranian, Poland. It is being operated by Orlen SA. Empower your strategies with our BMB (Barnowko - Mostno - Buszewo) Field report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Company Profile
Agthia Group PJSC – Company Profile
Agthia Group PJSC (Agthia Group), a subsidiary of General Holding Corp PJSC, is a manufacturer, distributor, and marketer of beverages and food products. The company’s product portfolio includes flour, animal feeds, yoghurt, tomato paste, chilli paste, fruit puree, frozen vegetables, fresh juices, juices, packaged water, flavored water, and frozen baked products. Agthia Group markets its products under Al Ain Water, Al Ain Zero, Al Ain Vitamin D, Al Ain Bambini, Alpin, Al Bayan, Grand Mills, Al Foah, BMB, Al Faysal...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMB-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BMB-101 Drug Details BMA-101 is under development for the treatment of undisclosed seizure disorder,...
-
Product Insights
Net Present Value Model: Fordadistrogene Movaparvovec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Fordadistrogene Movaparvovec Drug Details PF-06939926 (BMB-D001)...